Michael Paul Pieper

Michael Paul Pieper

Auto-generated profile, based on publicly available information

Michael Paul Pieper

Boehringer Ingelheim Pharma GmbH & Co. KG

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
JCJungmi Choi
Jungmi Choi
NMNaoki Matoba
Naoki Matoba
DSDaiki Setoyama
Daiki Setoyama
DWDaiki Watanabe
Daiki Watanabe
YOYuichiro Ohnishi
Yuichiro Ohnishi
MYMasamichi Yamamoto
Masamichi Yamamoto
Empagliflozin, a sodium-glucose co-transporter 2 inhibitor developed, has been shown to reduce cardiovascular events in patients with type 2 diabetes and established cardiovascular disease. Several studies have suggested that empagliflozin improves the cardiac energy state which is a partial cause of its potency. However, the detailed mechanism remains unclear. To address this issue, we used a mouse model that enabled direct measurement of cytosolic and mitochondrial ATP levels. Empagliflozin treatment significantly increased cytosolic and mitochondrial ATP levels in the hearts of db/db mice. Empagliflozin also enhanced cardiac robustness by maintaining intracellular ATP levels and the recovery capacity in the infarcted area during ischemic-reperfusion. Our findings suggest that empagliflozin enters cardiac mitochondria and directly causes these effects by increasing mitochondrial ATP via inhibition of NHE1 and Nav1.5 or their common downstream sites. These cardioprotective effects may be involved in the beneficial effects on heart failure seen in clinical trials.

14 May 2024 in Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
WFWalaa Fakih
Walaa Fakih
AMAli Mroueh
Ali Mroueh
DGDal-Seong Gong
Dal-Seong Gong
SKShinnosuke Kikuchi
Shinnosuke Kikuchi
MPMichael Paul Pieper
Michael Paul Pieper
LJLaurence Jesel
Laurence Jesel
Aims: Atrial fibrillation (AF), the most common cardiac arrhythmia favouring ischemic stroke and heart failure involves left atrial remodelling, fibrosis and a complex interplay between cardiovascular risk factors. This study examined whether activated factor X (FXa) induces pro-remodelling and pro-fibrotic responses in atrial endothelial cells (AECs) and human atrial tissues and determined the underlying mechanisms. Methods and results: AECs collected from porcine hearts and human right atrial appendages (RAA) from patients undergoing heart surgery. Protein expression levels were assessed by Western blot and immunofluorescence staining, mRNA levels by RT-qPCR, formation of reactive oxygen species (ROS) and NO using fluorescent probes, thrombin and angiotensin II generation by specific assays, fibrosis by Sirius red staining and senescence by senescence-associated beta-galactosidase (SA-β-gal) activity. In AECs, FXa increased ROS formation, senescence (SA-β-gal activity, p53, p21), angiotensin II generation and the expression of pro-inflammatory (VCAM-1, MCP-1), pro-thrombotic (tissue factor), pro-fibrotic (TGF-β and collagen-1/3a) and pro-remodelling (MMP-2/9) markers whereas eNOS levels and NO formation were reduced. These effects were prevented by inhibitors of FXa but not thrombin, protease-activated receptors antagonists (PAR-1/2) and inhibitors of NADPH oxidases, ACE, AT1R, SGLT1/SGLT2. FXa also increased expression levels of ACE1, AT1R, SGLT1/2 proteins which were prevented by SGLT1/2 inhibitors. Human RAA showed tissue factor mRNA levels that correlated with markers of endothelial activation, pro-remodelling and pro-fibrotic responses and SGLT1/2 mRNA levels. They also showed protein expression levels of ACE1, AT1R, p22phox, SGLT1/2, and immunofluorescence signals of nitrotyrosine and SGLT1/2 colocalized with those of CD31. FXa increased oxidative stress levels which were prevented by inhibitors of the AT1R/NADPH oxidases/SGLT1/2 pathway. Conclusion: FXa promotes oxidative stress triggering premature endothelial senescence and dysfunction associated with pro-thrombotic, pro-remodelling and pro-fibrotic responses in AECs and human RAA involving the AT1R/NADPH oxidases/SGLT1/2 pro-oxidant pathway. Targeting this pathway may be of interest to prevent atrial remodelling and the progression of atrial fibrillation substrate.

1 March 2025 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
NSNisha Sharma
Nisha Sharma
WLWenjin Liu
Wenjin Liu
XTXiao-Qing E. Tsai
Xiao-Qing E. Tsai
ZWZhou Wang
Zhou Wang
COConnor Outtrim
Connor Outtrim
YHYufeng Huang
Yufeng Huang
Whether combining an sGC activator with an SGLT2 inhibitor could better control diabetes-associated oxidative stress and NO-cGMP signal deficiency has not yet been explored. Using the type 2 diabetic db/db mouse model, this study underscores the sGC activator avenciguat as a novel therapy for diabetic nephropathy and liver injury beyond sGLT2 inhibitors. It also highlights the need for further investigation into the combined effects of these two treatments in managing diabetic complications.

23 May 2024 in Kidney360
Verified
Journal Article
Open access
MGMengyuan Ge
Mengyuan Ge
JMJudith Molina
Judith Molina
ITIan Tamayo
Ian Tamayo
Guanshi ZhangGuanshi Zhang
Guanshi Zhang
JKJin-ju Kim
Jin-ju Kim
AFAlessia Fornoni
Alessia Fornoni
Key Points: Linagliptin reduces kidney function decline and extends lifespan in Alport syndrome mice. Inhibiting the generation of glucose metabolites could serve as a potential therapeutic strategy for the treatment of Alport syndrome. Background: We previously demonstrated that empagliflozin (Empa), a sodium-glucose cotransporter-2 inhibitor, reduces intrarenal lipid accumulation and slows kidney function decline in experimental Alport syndrome (AS). In this study, we aimed to evaluate the renal protective benefits of linagliptin (Lina), a dipeptidyl peptidase-4 inhibitor in AS, and compare it with Empa. Methods: Metabolite distribution in kidney cortices was assessed using mass spectrometry imaging. We examined albuminuria and histological changes in kidneys from AS mice treated with Lina and/or Empa or vehicle. Results: Several metabolites, including adrenic acid and glucose, were increased in renal cortices of AS mice compared with wild-type (WT) mice, whereas eicosapentaenoic acid levels were decreased. In addition, a redistribution of adrenic acid from the glomerular compartment in WT mice to the tubulointerstitial compartment in AS mice was observed. Both Lina and Empa treatments were found to reduce albuminuria to extend the survival of AS mice for about 10 days and to decrease glomerulosclerosis and tubulointerstitial fibrosis compared with WT mice. There were no significant differences with regard to the renal phenotype observed between Empa- and Lina-treated AS mice, and the combination of Lina and Empa was not superior to individual treatments. In vitro experiments revealed that dipeptidyl peptidase-4 is expressed in podocytes and tubular cells derived from both AS and WT mice. Differently from what we have reported for Empa, Lina treatment was found to reduce glucose-driven respiration in AS tubular cells but not in AS podocytes. Conclusions: Renal expression patterns and spatial distribution of several metabolites differ in AS compared with WT mice. Although Lina and Empa treatments similarly partially slow the progression of kidney disease in AS, the metabolic mechanisms conferring the protective effect may be different.

1 September 2017
Verified
Conference Paper
Closed access
RGReinoud Gosens
Reinoud Gosens
LKLoes Kistemaker
Loes Kistemaker
CECarolina Elzinga
Carolina Elzinga
CTChristofer S Tautermann
Christofer S Tautermann
MPMichael Pieper
Michael Pieper
HMHerman Meurs
Herman Meurs
The bronchodilator drug tiotropium has been suggested to bind an allosteric site on the M3 muscarinic receptor, but its functional relevance is unclear. We hypothesized that binding to this allosteric site would have functional implications for its bronchoprotective effects and its interactions with LABAs. Methods: We used molecular dynamics simulation and contraction studies in bovine and human smooth muscle strips to study the interactions between acetylcholine and tiotropium. Results: Using molecular dynamics, we show that tiotropium binds to the allosteric site and thereby prevents acetylcholine entry into the orthosteric binding pocket. Thus, tiotropium has two receptor binding sites, both of which antagonize acetylcholine action. This resulted in a low (allosteric binding) and high (orthosteric binding) functional affinity of tiotropium in studies of methacholine induced contractions of airway smooth muscle, that were characterized by rapid versus slow kinetics of interaction between methacholine and tiotropium. Antagonism by tiotropium was insurmountable in nature, with methacholine failing to reach maximal response. This behaviour facilitated functional interactions of tiotropium with the β-agonist olodaterol, which substantially potentiated the bronchoprotective effect of tiotropium to a much greater extent than additive. This biphasic behaviour was not observed for glycopyrrolate or atropine. Conclusions: Tiotropium has two binding sites at the M3 receptor that both prevent acetylcholine action, which together with the slow dissociation kinetics contributes to insurmountable antagonism and enhanced functional interactions with β-agonists.

1 January 2003
Verified
Conference Paper
Open access
PDF file
KSKarl A. Stroetmann
Karl A. Stroetmann
MPMichael Pieper
Michael Pieper
VSVeli N. Stroetmann
Veli N. Stroetmann